Eikon Therapeutics (Series D)

Funding Details
Awarder
Inbox
Date Award
May 18, 2025
Vertical
Biotechnology
Funding URL
View Funding Page

Company Info
Founding Year
2019
Traction
Eikon has raised a total of $1.1bn since its founding, with significant funding rounds including $106m in Series C in 2023.
Founders
Eric Betzig
Company Description
Eikon Therapeutics is a US-based biotech company focused on advancing its portfolio of cancer candidates, including EIK1001, a TLR7/8 agonist currently in Phase III trials for melanoma.
Market
Cancer therapeutics
Location
United States
Coinvestors
Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital

Links
Back to Home Back to Biotechnology Deals View Funding Announcement